Remove 2014 Remove Drug Pricing Remove Magazine
article thumbnail

EC authorises Sydnexis’ paediatric myopia treatment

Pharmaceutical Technology

Founded in 2014, Sydnexis is a US-based company and has recently concluded the three-year primary endpoint of its Phase III trial of the low-dose atropine formulation. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. “Patent losses could sink Allergan”.